Kristina Ruuth | Ruth Palmer Labhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/kristina-ruuth/Kristina RuuthHugo Blox Builder (https://hugoblox.com)en-usTue, 20 Nov 2018 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/media/icon_hua1ac8766117554d27209418f2eeeba33_52656_512x512_fill_lanczos_center_3.pngKristina Ruuthhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/kristina-ruuth/Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathwayshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/phosphoproteome_alk/Tue, 20 Nov 2018 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/phosphoproteome_alk/Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinibhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_i1171t/Wed, 01 Aug 2018 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_i1171t/Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutationhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_y1278s/Mon, 30 Oct 2017 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_y1278s/The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCNhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/pf06463922_alk/Thu, 01 Sep 2016 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/pf06463922_alk/